Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30237% above fair value
$111.60−2.62 (-2.29%)
Close on Nov 13, 2026Market cap $7.00BP/E –Yield –
Twist Bioscience total assets
Total assets on the balance sheet at the end of each period.
Twist Bioscience's total assets was $672.44M at Jun 30, 2026. For fiscal 2025 it was $641.86M, up 4.5% from the year before. The highest annual figure on record is $961.38M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $641.86M | +4.5% |
| FY2024 | Sep 30, 2024 | $614.32M | -20.9% |
| FY2023 | Sep 30, 2023 | $776.40M | -19.2% |
| FY2022 | Sep 30, 2022 | $961.38M | +36.9% |
| FY2021 | Sep 30, 2021 | $702.10M | +76.0% |
| FY2020 | Sep 30, 2020 | $398.88M | +113.3% |
| FY2019 | Sep 30, 2019 | $186.99M | +61.5% |
| FY2018 | Sep 30, 2018 | $115.79M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $672.44M | +4.5% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $676.21M | +13.5% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $638.09M | +4.8% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $641.86M | +4.5% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $643.61M | +0.9% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $595.62M | -15.3% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $608.58M | -17.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $614.32M | -20.9% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $638.12M | -21.3% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $702.85M | -17.7% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $732.82M | -19.5% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $776.40M | -19.2% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $810.33M | -17.3% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $853.92M | -16.4% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $909.97M | +15.7% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $961.38M | +36.9% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $979.66M | +35.1% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $1.02B | +50.8% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $786.17M | +12.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $702.10M | +76.0% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $725.30M | +77.7% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $677.29M | +109.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $699.57M | +263.8% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $398.88M | +113.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $408.24M | +97.4% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $323.87M | +131.1% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $192.28M | +16.9% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $186.99M | +61.5% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $206.81M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $140.17M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $164.45M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $115.79M | – |
See a number that looks wrong?